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8 Abstract
9 Migraine is a debilitating neurological disorder, affecting 12% of Caucasian populations. It is well known that migraine has a strong
10 genetic component, although the type and number of genes involved is unclear. Our previous work has investigated dopamine related
11 migraine candidate genes and has reported a significant allelic association with migraine of a microsatellite localised to the promoter region
12 of the dopamine beta-hydroxylase (DBH) gene.
13 The present study performed an association analysis in a larger population of case-controls (275 unrelated Caucasian migraineurs versus
14 275 controls) examining two different genetic DBH polymorphisms (a functional insertion/deletion promoter and a coding SNP A444G
15 polymorphism). Although no significant association was found for the SNP polymorphism, the results showed a significant association
16 between the insertion/deletion variant and disease (χ2=8.92, P=0.011), in particular in migraine with aura (χ2=11.53, P=0.003) compared
17 to the control group. Furthermore, the analysis of this polymorphism stratified by gender, revealed that male individuals with the homozygote
18 deletion genotype had three times the risk of developing migraine, compared to females. The DBH insertion/deletion polymorphism is in
19 linkage disequilibrium with the previously reported migraine associated DBH microsatellite and this insertion/deletion polymorphism is
20 functional, which may explain a potential role in susceptibility to migraine.
21 © 2006 Published by Elsevier B.V.
22
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24
25 1. Introduction
26 Migraine is a common neurological disease affecting
27 more than 10% of the general population. In Western
28 countries, the overall migraine prevalence is 6–8% in men
29 and 15–25% in women [1]. This prevalence is highest
30 between the ages of 25 and 55, during the peak productive
31 years [2].
32 There are two main types of migraine distinguished and
33 classified by the International Headache Society [3]:
34 migraine without aura (MO) and migraine with aura (MA),
35 in which headache is preceded by transient focal neurologic
36symptoms. More than 70% of migraine patients are classified
37as the MO subtype, while MA occurs in 30% of migraineurs.
38During migraine attacks, an activation of the cerebral
39structures of the thalamus in response to excessive afferent
40stimulation or of the hypothalamus in response to changes in
41the internal environment is believed to occur [4]. These
42responses involve a modulation of the intracranial perivas-
43cular nerve, initiating a neurogenic inflammation and
44causing an increase in the diameter of the meningeal blood
45vessels. The vasodilatation in turn, allows propagation of the
46nociceptor factors (liberated in the blood circulation),
47causing headache pain. Several neurobiologic systems are
48part of these events, including serotoninergic, acetylcholi-
49nergic and catecholaminergic (dopamine, DA, and norepi-
50nephrine, NE). In fact, NE can mediate many important
51functions in the central and peripheral nervous system. It is
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52 the major neurotransmitter of the sympathetic division of the
53 autonomous nerve system, where its release regulates
54 vascular tone and cardiac contractility among other vital
55 functions. In the central nervous system, NE is localised
56 within several neurons in the hindbrain and the midbrain,
57 and it participates in the regulation of several vital
58 physiological functions (cardiac rhythm, awake–sleep
59 cycle, and cognition…) [5]. Disturbances in the noradrener-
60 gic system can contribute to diverse pathologies including
61 hypertension [6], hyperactivity sleep disorders [7] and
62 migraine [8]. Actually, in some migraineurs, the level of
63 plasma noradrenaline levels has been measured as being
64 significantly lower in patients compared to controls [9],
65 indicating a sympathetic dysfunction. In addition, significant
66 differences of serum dopamine beta-hydroxylase activity
67 (DBH) have been observed in migraine (MO and MA)
68 patients compared with healthy control subjects [10].
69 DBH plays an important role in the noradrenergic system.
70 This enzyme is localised within the membrane fraction of NE
71 and epinephrine producing neurons and neurosecretory cells,
72 where it catalyses the conversion of dopamine to NE [11,12].
73 DBH may be as important as dopamine and NE themselves
74 in the dysfunctions of the catecholamine pathway, notably in
75 nervous and mental disorders.
76 The gene encoding DBH, is located on chromosome 9q34
77 [13], and is composed of 12 exons with a length of
78 approximately 23 kb. DBH activity levels have been
79 reported to vary widely among different individuals [14].
80 Additional population studies led to the conclusion that the
81 level of individual DBH activity has a strong genetic
82 background [15,16].
83 While the mode of transmission of migraine is widely
84 believed to be multifactorial, a role for a major susceptibility
85 gene has been postulated. Based on pharmacological
86 evidence [17], several genetic association studies have
87 investigated a potential pathogenic role of the dopaminergic
88 system in migraine. Association studies of several receptor
89 genes have been performed in different populations, with
90 some conflicting results. A positive association of the D2 DA
91 receptor gene with MA has been reported in case controlled
92 [17] and family based [18] studies. However, several
93 negative associations studies for the dopaminergic transport-
94 er and for the D2, D3 and D4 dopaminergic receptors [19]
95 have also been observed.
96 Several functional polymorphisms have been reported for
97 the DBH gene (cf review: [20]). The first association
98 between DBH alleles of a short tandem repeat (STR), and
99 DBH plasma concentration was observed in a unrelated
100 British population [21]. Cubells et al. [22] confirmed that this
101 STR polymorphism affected plasma enzyme activity.
102 Cubells et al. [22] also investigated another DBH polymor-
103 phism— a promoter insertion/deletion polymorphism. They
104 showed that this promoter polymorphism was also function-
105 al, showing that an individual with the deletion of both
106 alleles had only half of the mean plasma enzyme activity
107 compared with a homozygote with the insertion/insertion
108genotype. A previous study in our lab examined the
109prevalence of different alleles of both markers, the DBH
110STR and DBH insertion/deletion in an association study with
111142 unrelated migraineurs and 136 controls plus a TDT-
112analysis of 296 subjects (263 affected) from 82 families of
113migraineurs. The results showed a distortion of allele
114transmission of the microsatellite (STR) marker in indivi-
115duals suffering from both migraine with or without aura [23].
116In the present study, we investigated the insertion/deletion
117polymorphism using nearly twice as large a population of
118unrelated subjects: 275 migraineurs versus 275 controls, and
119we also investigated a synonymous single base substitution
120(A→G) at the 3′ end of DBH exon 2, previously associated
121with both serum and cerebrospinal fluid levels of DBH.
1222. Methods
1232.1. Subjects
124The study protocol was approved by Griffith University's
125ethics committee for experimentation on humans. All
126individuals were of Caucasian origin and gave informed
127consent before participating in the research. Migraineurs were
128diagnosed as having either MA or MO, based strictly on
129criteria specified by the International Headache Society (IHS)
130[3]. All individuals were grouped together and phenotyped as
131being affected with typical migraine (MA+MO=Migraine),
132aswell as being examined separately asMAorMOsubgroups.
133The study population was comprised of 275 migraineurs (166
134MA/103 MO) and 275 unrelated control individuals. To mini-
135mise potential bias from population stratification, the control
136group was matched for sex, age (+/−5 years) and ethnicity.
1372.2. Markers/genotyping
138The study investigated two different polymorphisms at the
139DBH gene locus. One is a 19 nucleotide insertion–deletion
140approximately (named DBH2) 4.5 kilobases upstream of the
141transcriptional start site [24]. The DBH2 polymorphism was
142detected by PCR amplification using the following primers
143(cf Genebank Accession No. X63418) with the forward
144primer labelled with a fluorescent dye at its 5′-end:
1457
149Sense: 5′-GCA AAA GTC AGG CAC ATG CAC C-3′
151Antisense: 5′-GTC AGC GAG ATG GGG AGG TGG A-3′
52
153
154The PCR reactions (10 μl final volume) contained 1 μl of
155genomic DNA (20 μg/μl), 0.4 μl of each primer (5 mM),
1560.08 μl of Taq polymerase (5 U/μl), 5 μl of Buffer
157(MasterAmp, 2× PCR PreMix B; Epicentre, Madison,
158USA), 3.12 μl H2O. Temperature conditions were: 5 min
159at 94 °C for the denaturation; 35 cycles of 30 s at 94 °C; 30 s
160at 60 °C; 1 min at 72 °C for the elongation. The length of the
161resulting fragments was analysed by 310 Genetic Analyzer.
162The second marker was a synonymous SNP (ref SNP
163database, rs 1108580) at the position 444 (A→G), named in
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164 this study DBH3. The PCR analysis of DBH3 was carried out
165 using a modification of a previously described method [22].
166 The PCR reactions (10 μl final volume) contained 2 mmol/
167 l MgCl2, 0.625 mol/l of each primer, 200 mol/l dNTPs, 1 U of
168 Taq polymerase and approximately 20 μg of genomic DNA.
169 Primers were:
1702
174 Sense:
175 5′-TCCTTCATGCCTGGAGCCCAGTGCTTGTCT-3′
177 Antisense:
178 5′-GACAGGAAAGGTACTATGACATTGGCACAG-3′179
180 Thermal cycling was performed with an initial denatur-
181 ation of 30 s at 94 °C, followed by 35 cycles of 30 s at 94 °C,
182 30 s at 60 °C, 30 s at 72 °C, and a terminal extension of 2 min
183 at 72 °C. The PCR products were digested with EcoNI and
184 analysed by electrophoresis on 3% agarose gels. Ethidium
185 bromide stained gels were digitally imaged and manually
186 scored for genotypes. The PCR products were 207 bp in size.
187 The DBH3 A alleles did not digest with EcoNI, whereas G
188 alleles digested to give 169 bp and 38 bp fragments.
189 2.3. Statistical analysis
190 To detect association between each marker and migraine,
191 we performed chi-square (χ2) analysis to test for significant
192 differences in allele and genotype frequencies in case versus
193 control results [25]. χ2 provides the likelihood of a deviation
194 in the distribution of the same attributes in different classes
195 (e.g. allelic frequencies in controls versus affected subjects).
196 If the probability (P-volume) of an equal distribution
197 between the two groups is below a determined significance
198level α (in percent), the statistical output will show enough
199significance to assume LD and therefore association.
200We performed χ2 analysis for migraineurs MA, MO and
201combined migraine groups versus control subjects for the
202DBH2 and DBH3 polymorphisms. We also tested for linkage
203disequilibrium between tested markers using the Graphical
204Overview of Linkage Disequilibrium (GOLD) program, a
205new bioinformatic software to analyse dense genetic maps.
206In addition, the GOLD program provides a distinct graphical
207representation of disequilibrium patterns [26]. For this
208analysis, we included data found in our previous genotyping
209of the microsatellite polymorphism (DBH1), localised at
210118 bp downstream of the DBH2 marker [24] and which we
211had previously reported to be significantly associated with
212migraine (Lea, 2000).
213In total, we compared each of the two markers in controls
214with three different case groups of the population (MA, MO,
215Migraine (MO+MA)). Therefore, the standard significance
216level of 5% has been adjusted to α=0.05 / (2*3)=0.008,
217according to the application of Bonferroni correction for
218multiple testing, to provide evidence for association of the
219DBH polymorphisms with migraine susceptibility.
220Results were also tested for Hardy–Weinberg Equilibrium
221(HWE) investigating genotype frequencies of the DBH2 and
222DBH3markers to detect a deviation from the normal genotype
223distribution in the population and odds ratios were calculated
224to characterise the distribution of a distinct genotypes in
225different phenotypic subgroups of the population.
2263. Results
227Two markers 4.5 kb upstream of the starting point and a
228marker in the coding of the DBH gene, were analysed for
229association with migraine in a large population (275
230migraineurs versus 275 healthy individuals) of Australia
231Caucasians. Genotypes for both DBH markers were
232determined in the migraine case and control populations.
233The distribution of DBH2 and DBH3 genotypes in the
234studied population did not deviate significantly from the
235Hardy–Weinberg Equilibrium (PN0.05).
236Tables 1 and 1a represent the results of the allelic and
237genotypic frequency distribution of DBH2. Results showed
238no association of DBH2 genotype with migraine taking into
Table 1t1:1
Distribution of the 19-base pair (bp) insertion/deletion polymorphism (DBH2)
in migraineurs and controls of original sample (MO migraine without aura,
MA migraine with aura)t1:2
t1:3 Group N Genotypes N
(alleles)
Alleles
t1:4 Deletion
(11)
12 Insertion
(22)
Deletion Insertion
t1:5 Migraine 269 65
(24%)
110
(41%)
94
(35%)
538 240
(45%)
298
(55%)
t1:6 Male 72 18
(25%)
34
(47%)
20
(28%)
144 70
(49%)
74
(51%)
t1:7 Female 197 47
(24%)
76
(38%)
74
(38%)
394 170
(43%)
224
(57%)
t1:8 MA 166 45
(27%)
63
(38%)
58
(35%)
332 153
(46%)
179
(54%)
t1:9 MO 103 20
(19%)
47
(46%)
36
(35%)
206 87
(42%)
119
(58%)
t1:10 Control 265 41
(15%)
138
(52%)
86
(33%)
530 220
(42%)
310
(58%)
t1:11 Male 72 6
(8%)
41
(57%)
25
(35%)
144 53
(37%)
91
(63%)
t1:12 Female 193 35
(18%)
97
(50%)
61
(32%)
386 167
(43%)
219
(57%)
t1:13 Total case
versus
Control
χ2=8.92, P=0.011 χ2=1.03, P=0.306
Table 1a t2:1
Chi-squared (χ2) analysis of all migraine groups and of gender groups
against controls for the DBH 19 bp insertion/deletion polymorphism t2:2
t2:3Group Frequency comparison
t2:4Genotype Allele
t2:5Combined χ2=8.92, P=0.011 χ2=1.03, P=0.306
t2:6MA χ2=11.48, P=0.003 χ2=1.74, P=0.187
t2:7MO χ2=1.45, P=0.484 χ2=0.03, P=0.850
t2:8Males χ2=7.21, P=0.027 χ2=4.10, P=0.042
t2:9Females χ2=5.52, P=0.063 χ2=0.001, P=0.973
There is no significance in the allele frequencies of this marker however, the
genotype distribution for MA shows a positive association (χ2=11.48,
P=0.003) between marker and disease. t2:10
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239 the account the corrected significance level (α=0.008)
240 (χ2 =8.92, 2 df, P=0.011), and also for the allelic frequencies
241 (χ2 =1.03, 2 df, P=0.306). However, the results indicated a
242 significant association of MA genotypes compared to
243 controls (χ2 =11.48, 2 df, P=0.003) (Table 2a). Subjects
244 with two copies of the deletion genotype had approximately
245 2 fold increased risk of MA compared to controls (OR=2.03,
246 95% CI 1.26–3.28), and a 1.74 increased risk for all
247 migraineurs combined (OR=1.74, 95% CI 1.13–2.7),
248 compared to controls. When the genotype frequencies for
249 DBH2 were analysed by gender, a significant association
250 was found for all combined migraine compared to controls in
251 males (χ2 =7.21, 2 df, P=0.027), but was not significant in
252 female groups (χ2 =5.87, 2 df, P=0.063) (Table 2a). With
253 regard to the subtype of migraine and the gender, the
254 association with MA was also more significant in the male
255 group (χ2 =11.44, 2 df, P=0.003) than in the female group
256 (χ2 =5.87, 2 df, P=0.053).
257 As is shown in Table 2, there was no significant
258 association between both genotype and allelic frequencies
259 of DBH3 and migraine (χ2 =1.16, 2 df, P=0.56; χ2 =0.00,
260 2 df, P=0.986 respectively). When we analysed by gender
261 and by subtype of migraine, no significant association was
262 similarly observed for DBH3 genotype and allelic distribu-
263 tion (PN0.0125) (Table 2a), except for the male sub-
264 population for genotype distribution (P=0.033).
265 LD was calculated for all of the studied DBH genetic
266 markers (DBH1 from our previous study, and DBH2 and
267 DBH3 from the present study). The D′ value between DBH1
268 and DBH2 (D′=0.458, P=0.00001) is nearly twice as high
269 as for DBH1 versus DBH3 (D′=0.293, P=0.00001) and
270 DBH2 versus DBH3 (D′=0.315, P=0.00001), suggesting a
271much stronger linkage disequilibrium between DBH1 and
272DBH2.
2734. Discussion
274The existence of dopaminergic hypersensitivity in
275migraine is recognised on a pharmacological basis [17,27],
276and some studies have reported a genetic association
277between migraine and molecular variations in DA genes,
278e.g. with the D2 dopaminergic receptor [17,18] and D4
279dopaminergic receptor [19]. Our previous study has also
280reported an allelic association for an STR marker in the DBH
281gene (DBH1 marker) with typical migraine in an unrelated
282case-control population and in an independent sample of 82
283families affected with migraine [23]. In this study, we
284analysed the distribution of genotype and allelic frequencies
285of two additional DBH markers (DBH2 and DBH3) in a
286large case-control population of unrelated people.
287In contrast to our earlier study which also tested the
288DBH2 marker but in a smaller population (177 cases, 182
289controls), results from the present study showed an
290association between the DBH2 genotypic deletion marker
291and MA subtype (P=0.003). However, no association was
292found for the allelic frequency distribution between MA and
293controls, except for the male sub-population (P=0.0033).
294This is a curious funding and may result from a higher
295number of heterozygous genotype individuals in migraine
296and controls group, which may mask the significant
297association between the deletion allele and the disease.
298Alternatively it may indicate that only the homozygous
299deletion genotype is generally associated with migraine, or
300that the association effect is gender specific.
301When the genotype data for DBH2 were processed by
302gender only in the subtype MA group, the strong
303disequilibrium between the marker and the disease came
304up strongly significant for the male group (P=0.003), but not
305for the female group (P=0.053). Therefore, the analysis of
306the difference in DBH2 polymorphism stratified by gender
307revealed that male individuals with the homozygous deletion
308genotype are at a greater risk of developing migraine
309(OR=3.67, 95% CI 1.36–9.88), than the female group
310(OR=1.41, 95% CI 0.86–2.3).
Table 2t3:1
Distribution of SNP (rs 1108580) polymorphism (DBH3) in migraineurs and
controls of original sample (MO migraine without aura, MA migraine with
aura)t3:2
t3:3 Group N Genotypes N
(alleles)
Alleles
t3:4 11 12 22 1 2
t3:5 Migraine 213 51
(24%)
100
(47%)
62
(29%)
426 202
(47%)
224
(53%)
t3:6 Male 65 11
(17%)
38
(58%)
16
(25%)
130 60
(46%)
70
(54%)
t3:7 Female 148 40
(27%)
62
(42%)
46
(31%)
296 142
(48%)
154
(52%)
t3:8 MA 135 29
(21%)
65
(48%)
41
(31%)
270 123
(46%)
147
(54%)
t3:9 MO 78 22
(28%)
35
(45%)
21
(27%)
156 79
(51%)
77
(49%)
t3:10 Control 227 60
(26%)
95
(42%)
72
(32%)
454 215
(47%)
239
(53%)
t3:11 Male 67 19
(28%)
24
(36%)
24
(36%)
134 62
(46%)
72
(54%)
t3:12 Female 160 41
(26%)
71
(44%)
48
(30%)
320 153
(48%)
167
(52%)
t3:13 Total case
versus
control
χ2=1.16, P=0.56 χ2=0.00, P=0.986
Table 2a t4:1
Chi-squared (χ2) analysis of all migraine groups and of gender group against
controls for the SNP (rs 1108580) polymorphism t4:2
t4:3Group Frequency comparison
t4:4Genotype Allele
t4:5Combined χ2=1.16, P=0.56 χ2=0.00, P=0.986
t4:6MA χ2=1.65, P=0.43 χ2=0.22, P=0.640
t4:7MO χ2=0.63, P=0.73 χ2=0.50, P=0.478
t4:8Males χ2=6.87, P=0.033 χ2=0.00, P=0.985
t4:9Females χ2=0.20, P=0.906 χ2=0.001, P=0.968
There is no significance in the allele and genotype frequencies of DBH3
marker compared to controls for most analyses, although males showed a
positive genotypic variation for the DBH3 marker. t4:10
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311 The homozygous deletion genotype of DBH2 increased
312 the risk of developing migraine in general ∼1.7 fold
313 (OR=1.74, 95% CI 1.13–2.7) and around 2 fold for MA
314 (OR=2.03, 95% CI 1.26–3.28). Considering the risk
315 according to gender, there was an increased risk to males
316 of 3.7 fold compared to females of around 1.4 fold. This
317 finding suggests that the deletion genotype of DBH2 is
318 associated with migraine (in particular to MA), with a
319 significantly increased susceptibility in males.
320 Results investigating the DBH3 marked showed no
321 significant difference between control and migraine groups
322 (for any subtype of migraine, PN0.05) in this study, although
323 there was again a genotypic association for this marker in the
324 male sub-population.
325 Analysis of LD between the studied genetic markers
326 reveals a moderate but significant linkage between DBH1
327 and 2 (D′=0.458, P=0.00001). However, this LD value is
328 decreased by more than 30% when linkage is measured
329 between DBH1 and 3 on one hand, and DBH2 and 3 on
330 another hand. Our previous association between DBH1 and
331 MA has been confirmed in this study and extended to the
332 marker DBH2, in linkage with DBH1. The co-associations of
333 DBH2 (promoter marker) and DBH3 (intragenic) with MA
334 have probably broken down.
335 Both of the genetic markers of DBH studied in this work,
336 have been reported to be associated with the differences in
337 plasma and CSF levels of DBH [22,28]. A single 10-kb block
338 spreading from DBH2 to DBH3 in the DBH gene has been
339 recently reported as being highly associated with the
340 phenotype of the enzyme (P=2.2×10− 10) [28]. This block
341 contains in particular the diallelic marker (SNP) −1021
342 C→T polymorphism, which accounts for 35%–52% of the
343 total phenotypic variance in plasma DBH activity in samples
344 from three different populations [28]. This functional
345 polymorphism has been associated with Parkinson's disease
346 [29]. A new intragenic non-synonymous SNP polymorphism
347 (+1603 C→T) has also been recently identified in exon 11 of
348 the DBH gene and has also associated with the phenotype of
349 the enzyme [30]. These markers have not yet been
350 investigated in migraine and clearly the present report and
351 past studies implicating this gene, indicate that further genetic
352 studies of DBH are warranted.
353 VaryingDBH activity levels have been postulated as being
354 involved in the migraine process [31]. A possible mechanism
355 of the enzyme's involvement in migraine to explain the
356 association between the reduced DBH activity and MA can
357 be explicated by the lesser amount of the end product NE due
358 to reduced activity in subjects with homozygous deletion of
359 DBH, which may lead to a hypofunction of the diffuse NE
360 system of the brain, previously reported in the literature
361 [9,32]. In addition, the increase of DA, resulting to the lower
362 enzyme activity in migraineurs with homozygous deletion
363 genotype, has already been shown to be positively correlated
364 with the severity of migraine attacks [33,34].
365 We conclude that the DBH2 homozygous deletion
366 genotype of the DBH gene is a genetic risk factor for the
367MA migraine subtype. Furthermore, men carrying the
368homozygous deletion genotype have a higher risk of being
369affected by migraine than women. Our results support a
370possible relationship between DBH activity and the patho-
371genesis of migraine. Further studies with larger samples and/
372or in another population, and also with the employment of
373other functional polymorphisms (−1021 C→T in promoter
374and +1603 C→T in coding region) of DBH gene must be
375undertaken to further investigate the relationship between
376DBH and the pathophysiology of migraine.
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